A new formulation, modified in excipients, of the medicinal product EUTIROX (levothyroxine) will be launched in May 2021, for all strenghts.

Since levothyroxine has a narrow therapeutic range, close monitoring and supervision of patients is required during the transition period in order to promptly detect possible thyroid imbalance and to evaluate if dosage adjustment is needed.

A Direct Healthcare Professional Communication (DHPC) and a patient information sheet, in Q&A format, are available here